748 |
Karina K., Ekaputri K., Biben J.A., Purwoko R.H., Sibuea T.P., Astuti S.L., Loho A.M., Limengka Y., Nelfidayani, Agustini S., Krisandi G., Maryam A., Rosadi I., Rosliana I., Sobariah S., Subroto W.R., Afini I., Widyastuti T., Zakiyah A., Ernanda D., Aini N., Jusryanti, Sulaeha A.D., Prestiani S.I., Donna I.M., Habibi, Mutiara M.S. |
57212146678;57285088000;55947833300;57286031400;57286487800;57285797400;57223264641;37029815800;57286487900;57286488000;57225009844;57286260300;57204720098;57186671400;57203547382;57218940654;57211068324;57211074403;57226293808;57226273639;57226289464;57286944600;57226286645;57283770100;57284210300;57285797500;57284210400; |
Evaluating the Safety of Intravenous Delivery of Autologous Activated Platelet-rich Plasma |
2021 |
Journal of Health Sciences |
11 |
2 |
|
61 |
65 |
|
2 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111033469&doi=10.17532%2fjhsci.2021.1276&partnerID=40&md5=b0a026ecaccc92d972564c5dfd1f4824 |
Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia; Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Faculty of Medicine, Universitas Pembangunan Nasional Veteran Jakarta, Jakarta, Indonesia; Pusat Kajian Stem Cell, Universitas Pembangunan Nasional Veteran Jakarta, Jakarta, Indonesia; Department of Biology, Faculty of Mathematics and Natural Sciences, Mulawarman University, Indonesia |
Karina, K., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia, Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia, Faculty of Medicine, Universitas Pembangunan Nasional Veteran Jakarta, Jakarta, Indonesia, Pusat Kajian Stem Cell, Universitas Pembangunan Nasional Veteran Jakarta, Jakarta, Indonesia; Ekaputri, K., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Biben, J.A., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Purwoko, R.H., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Sibuea, T.P., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Astuti, S.L., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Loho, A.M., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Limengka, Y., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Nelfidayani, Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Agustini, S., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Krisandi, G., Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Maryam, A., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Rosadi, I., Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia, Department of Biology, Faculty of Mathematics and Natural Sciences, Mulawarman University, Indonesia; Rosliana, I., Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia; Sobariah, S., Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia; Subroto, W.R., Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia; Afini, I., Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia; Widyastuti, T., Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia; Zakiyah, A., Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia; Ernanda, D., Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia; Aini, N., Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia; Jusryanti, Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Sulaeha, A.D., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Prestiani, S.I., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Donna, I.M., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Habibi, Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Mutiara, M.S., Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia |
Introduction: Autologous platelet-rich plasma (PRP) has been a growing trend in the field of medicine due to its broad range of application and is considered safe from bloodborne diseases. Furthermore, various studies have tried to optimize the use of autologous PRP through various preparation protocols, including PRP activation. However, most of the studies available have not evaluated the safety for intravenous delivery of PRP, especially autologous activated PRP (aaPRP). Therefore, this study aimed to evaluate the safety of intravenous delivery of aaPRP. Methods: Blood was drawn from each patient and aaPRP was isolated through calcium activation and light irradiation. Each aaPRP was administered intravenously to all patients. Adverse events were documented and analyzed. Results: Six hundred eleven patients participated in this study with a total of 4244 aaPRP therapies. Quality control of autologous aaPRP showed no platelets present after both calcium activation and light irradiation. No adverse events such as allergic reaction, infection, and coagulation problems were observed on all patients over the course of the study. Conclusion: Our results showed that intravenous administration of autologous aaPRP is safe even in patients with various pathological conditions. © 2021. Karina Karina, et al.; licensee University of Sarajevo - Faculty of Health Studies. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
Intravenous infusion; platelet-rich plasma; safety |
|
University of Sarajevo - Faculty of Health Studies |
22327576 |
|
|
Article |
Q4 |
112 |
28273 |
|
|